AnaptysBio, Inc. (ANAB) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares are up ~18% over 21 days and ~13% above the 21‑day SMA after a large one‑day jump, with clear near‑term catalysts: a Q2 2026 spin‑off of First Tracks Biotherapeutics, active Phase 1b enrollment, and ongoing Delaware Chancery litigation milestones. Event‑driven traders can target additional upside on spin‑off and legal/process news, with elevated pullback risk from high leverage and rich valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Liquidity Buffer • Cost Pressure • Negative FCF ANAB has ample liquidity and a cash-rich balance sheet, but rising R&D and operating costs are driving widening losses, negative free cash flow, and an expensive valuation despite solid near-term solvency.
Price Behavior
Key Price Behavior Insights: • Lower highs • Low-50s support • Reclaim needed Support Level: $50-$51 Resistance Level: $57-$60 Over the last month, ANAB has fallen in a clear downtrend from the upper-$60s to about $50, with $57-$60 now resistance, $50-$51 near-term support, and a bounce only likely if $53-$55 is reclaimed.
Sentiment & News
Key News Insights: • Leadership changes • Collaboration focus • Analyst upside ANAB's latest headlines highlight leadership changes, Q1 updates, collaboration-driven operations, and growing analyst optimism around potential upside from improving earnings estimates.
AI Summary
ANAB has shifted from a broad biotech pipeline to a much narrower royalty/collaboration story after the First Tracks spin-off, so the investment case now depends almost entirely on Jemperli economics, the imsidolimab FDA catalyst, and whether management can rein in cash burn and protect value in a more leveraged, less diversified structure.
Description
AnaptysBio is a clinical-stage biotechnology company developing therapeutic antibody candidates for inflammatory and immuno-oncology indications. Its pipeline includes programs directed at interleukin-36 receptor, modulators of PD-1 signaling, and BTLA, with assets progressing through preclinical and clinical milestones. The company maintains collaborations and licensing arrangements with major industry and research partners, and is headquartered in San Diego, California; it was incorporated in 2005.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 5 | Mar 12 | ANAB | AnaptysBio, Inc. | Shares are up ~18% over 21 days and ~13% above the 21‑day SMA after a large one‑day jump, with clear near‑term catalysts: a Q2 2026 spin‑off of First Tracks Biotherapeutics, active Phase 1b enrollment, and ongoing Delaware Chancery litigation milestones. Event‑driven traders can target additional upside on spin‑off and legal/process news, with elevated pullback risk from high leverage and rich valuation. | Closed | +11.4% |